Related Experiment Video
Updated: Jul 7, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Death and Venous Thromboembolism Analyses among Hospitalized COVID-19-Positive Patients: A Multicenter Study
Asma Alshahrani1, Abdullah Almoahzieie2,3, Hanan Alshareef4
1Department of Clinical Pharmacy, Faculty of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
Insights
Hospitalized COVID-19 patients face a significant mortality risk and a high incidence of venous thromboembolism (VTE), particularly those with cancer. Close monitoring for VTE is crucial in high-risk individuals.
Area of Science:
- Internal Medicine
- Infectious Diseases
- Cardiology
Background:
- Coagulation disorders are common in coronavirus disease 2019 (COVID-19) patients, especially those with severe symptoms.
- Hospitalized COVID-19 patients exhibit increased risks for thrombotic events.
- Understanding mortality and venous thromboembolism (VTE) in COVID-19 is critical.
Purpose of the Study:
- To determine the mortality rate in hospitalized COVID-19 patients.
- To establish the incidence of VTE in this population.
- To identify risk factors associated with VTE in COVID-19.
Main Methods:
- Retrospective observational cohort study.
- Inclusion of adult patients with laboratory-confirmed COVID-19.
- Multivariate logistic regression analysis to identify VTE predictors.
Main Results:
- 10.7% of 1024 COVID-19 patients died; 5.7% developed VTE.
- Mortality was higher in patients over 50, in the ICU, and on mechanical ventilation.
- Cancer patients had a significantly higher risk of VTE (aOR=2.614, p=0.039).
Conclusions:
- Hospitalized COVID-19 patients have a substantial mortality rate and VTE prevalence, particularly those with cancer.
- Anticoagulation therapy may not fully mitigate VTE risk in all COVID-19 patients.
- Vigilant monitoring for VTE is recommended for high-risk COVID-19 patients.
Background:
Coagulation disorders are frequently encountered among patients infected with coronavirus disease 2019 (COVID-19), especially among admitted patients with more severe symptoms. This study aims to determine the mortality rate and incidence and risk factors for venous thromboembolism (VTE) in hospitalized patients with COVID-19.
Methods:
This retrospective observational cohort study was conducted from March to July 2020 using a hospital database. All adult patients (>18 years old) with laboratory-confirmed COVID-19 were included. Laboratory data and the real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) for SARS-CoV-2 were obtained from medical records. The mortality rate and the incidence of VTE were established as study results. A multivariate logistic regression analysis was performed to identify predictors of thrombotic events.
Results:
rA total of 1024 confirmed COVID-19 patients were treated, of whom 110 (10.7%) were deceased and 58 patients (5.7%) developed VTE. Death occurred more frequently in patients older than 50 years and those admitted to the intensive care unit (ICU, 95%) and who received mechanical ventilation (62.7%). Multivariate analysis revealed that cancer patients were two times more likely to have VTE (adjusted odds ratio = 2.614; 95% CI = (1.048-6.519); p = 0.039). Other chronic diseases, such as diabetes, hypertension, and chronic kidney disease, were not associated with an increased risk of VTE.
Conclusions:
One-tenth of hospitalized COVID-19 patients were deceased, and VTE was prevalent among patients with chronic conditions, such as cancer, despite anticoagulation therapy. Healthcare professionals should closely monitor individuals with a high risk of developing VTE to prevent unwanted complications.
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Pneumonia III: Complications and Assessment
Anticoagulant Drugs: Low-Molecular-Weight Heparins

